Introduction:
We report interim 24-weeks efficacy data of ATLAS-M trial, a phase IV, multicentre, open-label, randomized study designed to show 48-weeks, non-inferior efficacy (margin of (12%) of treatment simplification to atazanavir/ritonavir (ATV/ r)'lamivudine (3TC) versus maintaining 3-drugs ATV/r-based cART. Methods: Subjects on ATV/r'2 NRTIs, without previous treatment failure (TF), with HIV-RNA B50copies/mL for 3 months and CD4 200 cells/mm 3 for 6 months were eligible. At baseline, patients were randomized to switch to ATV/r'3TC (arm one) or to maintain the original 3-drug regimen (arm two). Primary endpoint: proportion of patients free of TF at week 48. TF was defined as treatment modification for any reason, including virological failure (VF 0two consecutive HIV-RNA 50 copies/ mL or a single value 1000 copies/mL). Enrollment of 266 patients was planned. Results: A total of 266 patients (78% males, median age 44 years, median CD4 603 cells/mL, 79% treated with a tenofovircontaining backbone) were enrolled. At the time of analysis, 24 weeks data were available for 84 and 87 patients in arm one and two, respectively. At baseline, subjects in the two arms did not differ for the main characteristics. At 24 weeks, at the intention to treat analysis the proportion of patients free of TF was 91.7% (95% CI 85.8Á97.6) and 85.1% (95% CI 77.6Á92.6) in arm one and two, respectively (difference '6.6%, 95% CI (2.9/'16.1). VF was observed in two patients randomized to arm one (one at baseline, before treatment simplification) and one to arm two without resistance mutations. Clinical and laboratory adverse events occurred at similar rates in the two arms. At week 24, patients in arm one showed a greater increase in CD4 (mean change '90 vs '10 cells/mL, p00.007). A greater increase in total cholesterol ('18 vs (2 mg/dL, pB0.001), HDL ('4 vs '0 mg/dL, p00.001) and LDL ('12 vs '0 mg/dL, p00.001) was also observed in arm one without differences in other lipid parameters. Renal function showed a significant improvement in arm one (mean change in eGFR '5 vs (2 mL/min/1.73m 2 in arm two, p00.001). No significant differences in bilirubin levels or other laboratory parameters were observed between the two arms. Conclusions: This interim analysis suggests a 24-weeks non-inferior efficacy of treatment simplification to ATV/rit'3TC as compared to continuation of ATV/rit '2 NRTI in virologically suppressed patients. Follow-up until 48-weeks is scheduled to confirm these data. 
